[Form 4] Alignment Healthcare, Inc. Insider Trading Activity
Alignment Healthcare Chief Medical Officer Hyong (Ken) Kim reported the sale of 18,600 shares of the company’s common stock on 08/13/2025 under a Rule 10b5-1 trading plan adopted on 03/14/2025. The sales generated a weighted-average price of $15.0327 per share, with individual trades executed between $15.00 and $15.09. After the reported transactions, the reporting person beneficially owned 472,167 shares. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person and discloses the plan adoption date and the price range for the multiple sales.
- Transaction executed under a Rule 10b5-1 plan adopted 03/14/2025, indicating pre-authorized trades
- Disclosure of weighted-average price and per-share price range ($15.00 to $15.09) with an offer to provide detailed breakdown on request
- Disposition of 18,600 shares on 08/13/2025 reduced the reporting person’s holdings
- Beneficial ownership decreased to 472,167 shares following the reported sale
Insights
TL;DR: Insider sold a small portion of holdings under a pre-established 10b5-1 plan; disclosure is routine and non-material on its face.
The Form 4 shows a planned disposition of 18,600 shares executed on 08/13/2025 under a Rule 10b5-1 plan adopted 03/14/2025. The use of a 10b5-1 plan indicates trades were pre-authorized; the filing reports a weighted-average sale price of $15.0327 and a disclosed per-share price range of $15.00 to $15.09. Post-transaction beneficial ownership stands at 472,167 shares. For most investors this is a routine insider liquidity event rather than a corporate-change signal.
TL;DR: Disclosure meets Section 16 requirements and documents a Rule 10b5-1 plan sale with transparent price-range reporting.
The filing clearly identifies the reporting person’s role as Chief Medical Officer and confirms the transaction was executed pursuant to a 10b5-1 plan adopted 03/14/2025. The reporting includes a weighted-average sale price and a commitment to provide transaction-level pricing if requested, which enhances transparency. The filing is signed by an attorney-in-fact, consistent with permitted representation on Form 4 submissions.